Scientific publications
An engineered periosteum for efficient delivery of rhBMP-2 and mesenchymal progenitor cells during bone regeneration. Scientific Publication
Juan Antonio Romero-Torrecilla 1 2 , José María Lamo-Espinosa 3 4 , Purificación Ripalda-Cemboráin 1 2 3 4 , Tania López-Martínez 1 2 4 , Gloria Abizanda 1 2 , Luis Riera-Álvarez 3 , Sergio Ruiz de Galarreta-Moriones 5 , Asier López-Barberena 5 , Naiara Rodríguez-Flórez 5 6 , Reyes Elizalde 5 , Vineetha Jayawarna 7 , José Valdés-Fernández 1 2 , Miguel Echanove-González de Anleo 1 2 , Peter Childs 8 , Elena de Juan-Pardo 9 , Manuel Salmeron-Sanchez 7 , Felipe Prósper 1 2 4 10 11 , Emma Muiños-López 12 13 14 15 , Froilán Granero-Moltó 16 17 18 19
Abstract
During bone regeneration, the periosteum acts as a carrier for key regenerative cues, delivering osteochondroprogenitor cells and crucial growth factors to the injured bone. We developed a biocompatible, 3D polycaprolactone (PCL) melt electro-written membrane to act as a mimetic periosteum.
Poly (ethyl acrylate) coating of the PCL membrane allowed functionalization, mediated by fibronectin and low dose recombinant human BMP-2 (rhBMP-2) (10-25 μg/ml), resulting in efficient, sustained osteoinduction in vitro.
In vivo, rhBMP-2 functionalized mimetic periosteum demonstrated regenerative potential in the treatment of rat critical-size femoral defects with highly efficient healing and functional recovery (80%-93%). Mimetic periosteum has also proven to be efficient for cell delivery, as observed through the migration of transplanted periosteum-derived mesenchymal cells to the bone defect and their survival.
Ultimately, mimetic periosteum demonstrated its ability to deliver key stem cells and morphogens to an injured site, exposing a therapeutic and translational potential in vivo when combined with unprecedentedly low rhBMP-2 doses.
CITATION NPJ Regen Med. 2023 Sep 29;8(1):54. doi: 10.1038/s41536-023-00330-2
Our authors
